Skip Nav Destination
Issues
1 November 2014
-
Cover Image
Cover Image
Interrelation between vasculature, blood flow, proliferation, and hypoxia is shown in an HCT116 tumor xenograft 24 hours following irinotecan treatment. Irinotecan initially halts proliferation throughout the tissue but by 24 hours the S-phase fraction returns to near-control levels. The image was produced using multiplexed immunohistochemistry to illustrate the effects of drugs in the context of the tumor microenvironment. Greyscale images of the individual staining patterns were coregistered to produce the composite image shown here. HCT116 xenografts exhibit a corded architecture, where sheaths of tumor cells can be seen to surround individual vessels. Cells can survive to ∼150 m away from the blood vessels but become increasingly oxygen-deprived and eventually necrose. For details, see the article by Kyle and colleagues on page 2727. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Diana Cirstea; Loredana Santo; Teru Hideshima; Homare Eda; Yuko Mishima; Neeharika Nemani; Anuj Mahindra; Andrew Yee; Gullu Gorgun; Yiguo Hu; Hiroto Ohguchi; Rikio Suzuki; Francesca Cottini; Sylvie M. Guichard; Kenneth C. Anderson; Noopur Raje
Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification
Seung Tae Kim; Hye-Lim Jang; Su Jin Lee; Jeeyun Lee; Yoon-La Choi; Kyoung-Mee Kim; Jeonghee Cho; Se Hoon Park; Young Suk Park; Ho Yeong Lim; Masakazu Yashiro; Won Ki Kang; Joon Oh Park
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi; Nukinori Akiyama; Toshiyuki Tsukaguchi; Toshihiko Fujii; Kiyoaki Sakata; Hitoshi Sase; Takehito Isobe; Kenji Morikami; Hidetoshi Shindoh; Toshiyuki Mio; Hirosato Ebiike; Naoki Taka; Yuko Aoki; Nobuya Ishii
Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
Vianey Gonzalez-Villasana; Cristian Rodriguez-Aguayo; Thiruvengadam Arumugam; Zobeida Cruz-Monserrate; Enrique Fuentes-Mattei; Defeng Deng; Rosa F. Hwang; Huamin Wang; Cristina Ivan; Raul Joshua Garza; Evan Cohen; Hui Gao; Guillermo N. Armaiz-Pena; Paloma del C. Monroig-Bosque; Bincy Philip; Mohammed H. Rashed; Burcu Aslan; Mumin Alper Erdogan; Yolanda Gutierrez-Puente; Bulent Ozpolat; James M. Reuben; Anil K. Sood; Craig Logsdon; Gabriel Lopez-Berestein
Large Molecule Therapeutics
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Wim Dokter; Ruud Ubink; Miranda van der Lee; Monique van der Vleuten; Tanja van Achterberg; Danielle Jacobs; Eline Loosveld; Diels van den Dobbelsteen; David Egging; Ellen Mattaar; Patrick Groothuis; Patrick Beusker; Ruud Coumans; Ronald Elgersma; Wiro Menge; John Joosten; Henri Spijker; Tijl Huijbregts; Vincent de Groot; Michel Eppink; Guy de Roo; Gijs Verheijden; Marco Timmers
An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Suzie J. Scales; Nidhi Gupta; Glenn Pacheco; Ron Firestein; Dorothy M. French; Hartmut Koeppen; Linda Rangell; Vivian Barry-Hamilton; Elizabeth Luis; Josefa Chuh; Yin Zhang; Gladys S. Ingle; Aimee Fourie-O'Donohue; Katherine R. Kozak; Sarajane Ross; Mark S. Dennis; Susan D. Spencer
Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Hong Zhou; Khalid A. Mohamedali; Ana Maria Gonzalez-Angulo; Yu Cao; Mary Migliorini; Lawrence H. Cheung; Janine LoBello; Xiudong Lei; Yuan Qi; Walter N. Hittelman; Jeffrey A. Winkles; Nhan L. Tran; Michael G. Rosenblum
Cancer Biology and Signal Transduction
Companion Diagnostics and Cancer Biomarkers
A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Tuhina Mazumdar; Lauren A. Byers; Patrick Kwok Shing Ng; Gordon B. Mills; Shaohua Peng; Lixia Diao; You-Hong Fan; Katherine Stemke-Hale; John V. Heymach; Jeffrey N. Myers; Bonnie S. Glisson; Faye M. Johnson
Models and Technologies
Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Manuela Gridling; Scott B. Ficarro; Florian P. Breitwieser; Lanxi Song; Katja Parapatics; Jacques Colinge; Eric B. Haura; Jarrod A. Marto; Giulio Superti-Furga; Keiryn L. Bennett; Uwe Rix
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.